Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of Tryptophol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A known ✓ | P28223 | 4/20 | 0.58 |
| ▸ | HTR1A known ✓ | P08908 | 2/20 | 0.58 |
| ▸ | HTR2C known ✓ | P28335 | 2/20 | 0.54 |
| ▸ | HTR1D known ✓ | P28221 | 1/20 | 0.54 |
| ▸ | HTR1B known ✓ | P28222 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | BLM | P54132 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | MPO | P05164 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tryptophol SCHEMBL29364545 | 0.88 | HTR2A (0.67) | CYP1A2MEN1LMNAPKMTSHR | |
| Tryptophol SCHEMBL196126 | 0.88 | HTR2A (0.67) | CYP1A2MEN1LMNAPKMTSHR | |
| Tryptophol SCHEMBL15619233 | 0.87 | HTR2A (0.61) | CYP1A2MEN1LMNAPKMTSHR | |
| Tryptamine SCHEMBL9321966 | 0.86 | HTR2A (0.76) | CYP1A2MEN1LMNAPKMTSHR | |
| Tryptophol SCHEMBL21682597 | 0.86 | MEN1 (0.64) | CYP1A2MEN1LMNAPKMTSHR | |
| SCHEMBL1272559 | 0.81 | HTR2A (0.57) | CYP1A2MEN1LMNAPKMTSHR | |
| SCHEMBL30952641 | 0.81 | HTR2A (0.57) | CYP1A2MEN1LMNAPKMTSHR | |
| Indolylpropionic Acid SCHEMBL195854 | 0.80 | MAPT (0.61) | CYP1A2MEN1LMNAPKMTSHR | |
| SCHEMBL760892 | 0.80 | CYP19A1 (0.70) | CYP1A2MEN1LMNAPKMTSHR | |
| Tryptamine SCHEMBL27538374 | 0.79 | HTR2C (0.81) | CYP1A2MEN1LMNAPKMTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101370804-B | Novel aminophenyl derivatives as histone deacetylase inhibitors | JANSSEN PHARMACEUTICA NV | 2013-05-29 | — | — | CN | disclosed |
| US-8119650-B2 | Aminophenyl derivatives as novel inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA N.V. (BG) | 2012-02-21 | — | — | US | disclosed |
| CN-1993353-B | Substituted indolyl alkylamino derivatives as novel inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA NV | 2010-12-01 | — | — | CN | disclosed |
| EP-1981874-B1 | AMINOPHENYL DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA NV (BE) | 2009-05-27 | — | — | EP | disclosed |
| CN-101370804-A | Novel aminophenyl derivatives as histone deacetylase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2009-02-18 | — | — | CN | disclosed |
| US-20090018152-A1 | Aminophenyl Derivatives as Novel Inhibitors of Histone Deacetylase | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-01-15 | — | — | US | disclosed |
| EP-1981874-A1 | AMINOPHENYL DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | Janssen Pharmaceutica, N.V. (BE) | 2008-10-22 | — | — | EP | disclosed |
| WO-2007082878-A1 | AMINOPHENYL DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-26 | — | — | WO | disclosed |
| CN-1993353-A | Substituted indolyl alkylamino derivatives as novel inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA NV (BE) | 2007-07-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018152-A1 | Aminophenyl Derivatives as Novel Inhibitors of Histone Deacetylase | HDAC1, HDAC9, HDAC11 | HTR2A 2727/4885HTR1A 1796/4885HTR2C 3676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.